September 7, 2017
Biocartis product revenues grew 195% in first half 2017
Commenting on the H1 2017 results, Hilde Windels, interim Chief Executive Officer Biocartis (until 31 August 2017), said that the…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Biocartis
September 5, 2017
Biocartis gets FDA clearance for Idylla Respiratory
Biocartis Group got clearance for the Idylla Respiratory (IFV-RSV) Panel from the US Food and Drug Administration (FDA). Idylla Respiratory…
August 31, 2017
Biocartis CEO: MSI testing with Idylla shows great potential
Biocartis Group NV has published two study abstracts about the performance of its new set of biomarkers for microsatellite instability…
July 12, 2017
Biocartis can speed up Idylla platform in U.S.
Biocartis Group said on Wednesday that on the day before, July 11, 2017 the US FDA published a final list of devices that it has exempted from 510(k) premarket notification requirements in accordance with the US 21st Century Cures Act (signed into US law 13 December 2016).
March 2, 2017
Biocartis’s CEO changes role, net loss inreased to €50M in 2016. New Idyla launched
Biocartis Group has posted net income loss of €50.2 million for 2016, which is loss increase compared to last years €39.7 million net loss.
December 22, 2016
Biocartis submits 510(k) to FDA, expands European hospitals deal with Amgen
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
December 15, 2016
Biocartis CE-marks Idylla NRAS-BRAF Mutation Test
Biocartis has CE-marked its solid biopsy Idylla NRAS-BRAF Mutation Test. On Thursday, Biocartis said that, together with the CE-marked Idylla…
December 14, 2016
J&J shareholding in Biocartis decreases
Johnson&Johnson has decreased its shareholding in Biocartis, the Belgian drugmaker said on Wednesday. In a disclosure of a transparency notification,…
December 12, 2016
Short: Sycomore Asset Management’s share of Biocartis trigers transparency act
Biocartis Group NV said on Monday, in accordance with the Belgian Transparency Act, that Sycomore Asset Management now holds 3.01% of the…
October 11, 2016
Biocartis’ Idylla technology could enhance molecular diagnostic testing
Biocartis Group NV, a Belgian innovative molecular diagnostics company has published a comparative study organised by AstraZeneca where 12 different KRAS mutation detecting technologies, including Next-Generation Sequencing (NGS) and quantitative Polymerase Chain Reaction (PCR), were compared for the detection of KRAS mutations in lung cancer, using blinded samples.